AZD4144 + rosuvastatin

AZD4144 + rosuvastatin is an investigational **combination therapy** comprised of AZD4144, a novel small molecule agent under clinical development, and rosuvastatin, an established HMG-CoA reductase inhibitor (statin). This combination is being studied to assess the pharmacokinetic (PK) interactions and safety profile when both agents are co-administered in healthy participants. AZD4144's precise mechanism of action has not been fully disclosed, but clinical studies are investigating its effects on inflammatory biomarkers such as IL-6, IL-18, and hsCRP. Rosuvastatin reduces cholesterol levels by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, leading to decreased LDL cholesterol and cardiovascular risk.